Halozyme and Oruka sign agreement for Hypercon technology
Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.